Mlecnik, Bernhard
Equipe Labellisée Ligue Contre le Cancer,
France
2025 Rank: 99,341
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3,021 out of 355,674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 99,341 | 104,626 |
| Total Cites | 2,088 | 2,160 |
| H-index | 19 | 19 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 15 | 15 |
| Total Cites to Single+First Authored Papers | 207 | 223 |
| Number of Single+First+Last Authored Papers | 16 | 16 |
| Total Cites to Single+First+Last Authored Papers | 263 | 279 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1,722 | 1,735 |
| Ratio of Total Citations to Distinct Citing Papers | 1.21 | 1.24 |
| Self-Citation Percentage |
3.33%
|
|
Mlecnik, Bernhard
Inserm,
France
2024 Rank: 71,381
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2,342 out of 334,837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 71,381 | 78,239 |
| Total Cites | 2,601 | 2,713 |
| H-index | 20 | 20 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 15 | 15 |
| Total Cites to Single+First Authored Papers | 249 | 279 |
| Number of Single+First+Last Authored Papers | 16 | 16 |
| Total Cites to Single+First+Last Authored Papers | 335 | 365 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2,054 | 2,080 |
| Ratio of Total Citations to Distinct Citing Papers | 1.27 | 1.30 |
| Self-Citation Percentage |
4.13%
|
|
Mlecnik, Bernhard
Inserm,
France
2023 Rank: 55,485
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1,970 out of 312,644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 55,485 | 62,911 |
| Total Cites | 3,025 | 3,135 |
| H-index | 21 | 21 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 335 | 354 |
| Number of Single+First+Last Authored Papers | 15 | 15 |
| Total Cites to Single+First+Last Authored Papers | 451 | 471 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2,401 | 2,433 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.29 |
| Self-Citation Percentage |
3.51%
|
|
Mlecnik, Bernhard
Inovarion,
France
2022 Rank: 46,649
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1,772 out of 293,195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 46,649 | 51,837 |
| Total Cites | 3,230 | 3,344 |
| H-index | 22 | 23 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 368 | 391 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 501 | 524 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2,366 | 2,394 |
| Ratio of Total Citations to Distinct Citing Papers | 1.37 | 1.40 |
| Self-Citation Percentage |
3.41%
|
|
Mlecnik, Bernhard
Inovarion,
France
2021 Rank: 56,555
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2,024 out of 271,773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 56,555 | 59,810 |
| Total Cites | 4,541 | 4,874 |
| H-index | 24 | 25 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 603 | 680 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 792 | 869 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3,241 | 3,311 |
| Ratio of Total Citations to Distinct Citing Papers | 1.40 | 1.47 |
| Self-Citation Percentage |
6.83%
|
|
Mlecnik, Bernhard
Sorbonne Universite,
France
2020 Rank: 65,721
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2,293 out of 230,678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 65,721 | 69,096 |
| Total Cites | 2,879 | 3,044 |
| H-index | 21 | 22 |
| Hm-index | 2 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 11 | 11 |
| Total Cites to Single+First Authored Papers | 382 | 418 |
| Number of Single+First+Last Authored Papers | 12 | 12 |
| Total Cites to Single+First+Last Authored Papers | 515 | 552 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2,061 | 2,099 |
| Ratio of Total Citations to Distinct Citing Papers | 1.40 | 1.45 |
| Self-Citation Percentage |
5.42%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.